1,4-dioxaspiro[4.4]nonane-7,8-diyl dimethanol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-dioxaspiro[4.4]nonane-7,8-diyl dimethanol
• 英文别名: 1,4-Dioxaspiro[4.4]nonane, 7,8-bis(hydroxymethyl)-；[8-(hydroxymethyl)-1,4-dioxaspiro[4.4]nonan-7-yl]methanol
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: VEAUZHKVSJXEPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,4-dioxaspiro[4.4]nonane-7,8-diyl dimethanol 在 三乙胺 作用下， 生成 1,4-Dioxaspiro[4.4]nonane-7,8-diylbis(methylene) Dimethanesulfonate
  参考文献：
  名称：

  SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS

  摘要：

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开号：

  US20230303509A1
• 作为产物：
  描述：

  3,4-Dimethoxycarbonylcyclopentanon-ethylenketal 生成 1,4-dioxaspiro[4.4]nonane-7,8-diyl dimethanol
  参考文献：
  名称：

  SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS

  摘要：

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开号：

  US20230303509A1

文献信息

• RIPK1抑制剂
  申请人：上海齐鲁制药研究中心有限公司

  公开号：CN116640156A

  公开（公告）日：2023-08-25

  本发明提供一类式(I)所示的具有RIPK1抑制活性的新型化合物，含有所述化合物的药物组合物、制备所述化合物的有用中间体以及利用本发明化合物治疗由RIPK1介导的相关疾病的方法。
• SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS
  申请人：NiKang Therapeutics, Inc.

  公开号：US20230303509A1

  公开（公告）日：2023-09-28

  The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.